WO2005079390A2 - Inhibition of fgf signaling - Google Patents

Inhibition of fgf signaling Download PDF

Info

Publication number
WO2005079390A2
WO2005079390A2 PCT/US2005/004682 US2005004682W WO2005079390A2 WO 2005079390 A2 WO2005079390 A2 WO 2005079390A2 US 2005004682 W US2005004682 W US 2005004682W WO 2005079390 A2 WO2005079390 A2 WO 2005079390A2
Authority
WO
WIPO (PCT)
Prior art keywords
fgf
sulfl
exogenous
signaling
fgf2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/004682
Other languages
English (en)
French (fr)
Other versions
WO2005079390A3 (en
Inventor
Charles P. Emerson, Jr.
Xingbin Ai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston Biomedical Research Institute Inc
Original Assignee
Boston Biomedical Research Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Biomedical Research Institute Inc filed Critical Boston Biomedical Research Institute Inc
Priority to EP05713533A priority Critical patent/EP1742961A4/en
Priority to CA002555417A priority patent/CA2555417A1/en
Priority to JP2006553327A priority patent/JP2007522243A/ja
Publication of WO2005079390A2 publication Critical patent/WO2005079390A2/en
Anticipated expiration legal-status Critical
Publication of WO2005079390A3 publication Critical patent/WO2005079390A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)

Definitions

  • Sulfl is secreted through the Golgi and is docked on the ceil surface through its distinctive hydrophilic domain, and Sulfl functions as a 6-0 endosulfatase, with substrate specificity for trisulfated ldoA2S-GlcNS6S disaccharide units of HS/heparin.
  • the avian orthoiog, QSulfl is required for Wnt-dependent gene expression in muscle progenitor cells of the quail embryo.
  • QSulfl activity remodels the 6- O sulfation states of cell surface HSPGs and decreases the binding affinity between Wnt ligand and HS.
  • QSulfl suppresses FGF2 (30 ng/ml), but not FGFR1K562E activation of Dp-ERK1/2.
  • QSulfl suppresses FGF2, but not FGFR1K562E induction of mesodermal markers, Brachyury and MyoD.
  • Whole embryo samples provided a positive control for mesodermal gene expression.
  • AP20187 (1.25 ⁇ M) activation of iFGFRI receptor induces Dp-ERK1/2 activation in the presence of QSulfl .
  • Methods disclosed herein for inhibiting FGF signaling in an FGF-responsive cell can be carried out in vitro. Inhibition of FGF signaling can be effectively achieved in an FGF-responsive cell in tissue culture.
  • FGF signaling is conserved in vertebrates and nonvertebrates, and, as such, methods for inhibiting the same may be carried out in tissue culture cells derived from either vertebrates or nonvertebrates. Examples of vertebrate cell lineages in which FGF signaling is converved include humans and mice. Examples of invertebrate cell lineages in which FGF signaling is conserved include C. elegans and Drosophila.
  • the methods disclosed herein for inhibiting FGF signaling may be used to study FGF signaling or for the development of therapeutics for modifying FGF signaling. The methods disclosed herein are not intended to be limited only for use with cells in culture.
  • Sulfl In addition to its function in embryos, Sulfl is also expressed in adult tissues and likely functions in pathophysiological processes such as cancer. Recent studies show HSuifl expression is suppressed in ovarian cancer cells, and that HSulfl overexpression in these cancer cells blocks ERK activation by FGF2 and EGF and inhibits proliferation (Lai et al., J. Biol. Chem. 278, 23107-23117 (2003)). The growth factor signaling functions of QSulfl in cells are based on its enzymatic activity and specificity for 6-0 desulfation of HS chains. Furthermore, QSulfl can enzymatically modify soluble heparin to produce potent inhibitors of angiogenesis.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PCT/US2005/004682 2004-02-13 2005-02-11 Inhibition of fgf signaling Ceased WO2005079390A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP05713533A EP1742961A4 (en) 2004-02-13 2005-02-11 LOCKING OF FGF SIGNALING
CA002555417A CA2555417A1 (en) 2004-02-13 2005-02-11 Inhibition of fgf signaling
JP2006553327A JP2007522243A (ja) 2004-02-13 2005-02-11 Ｆｇｆシグナリングの阻害

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54444904P 2004-02-13 2004-02-13
US60/544,449 2004-02-13

Publications (2)

Publication Number Publication Date
WO2005079390A2 true WO2005079390A2 (en) 2005-09-01
WO2005079390A3 WO2005079390A3 (en) 2006-12-14

Family

ID=34886037

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/004682 Ceased WO2005079390A2 (en) 2004-02-13 2005-02-11 Inhibition of fgf signaling

Country Status (5)

Country Link
US (1) US7968527B2 (https=)
EP (1) EP1742961A4 (https=)
JP (1) JP2007522243A (https=)
CA (1) CA2555417A1 (https=)
WO (1) WO2005079390A2 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009008496A1 (ja) * 2007-07-12 2009-01-15 Daiichi Sankyo Company, Limited 抗HSulf1抗体
WO2014138364A2 (en) 2013-03-06 2014-09-12 Genentech, Inc. Methods of treating and preventing cancer drug resistance
WO2015191986A1 (en) 2014-06-13 2015-12-17 Genentech, Inc. Methods of treating and preventing cancer drug resistance

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009011892A2 (en) * 2007-07-18 2009-01-22 Boston Biomedical Research Institute Use of suif proteins and heparan sulfate in gdnf-dependent neural innervation and protection
WO2010003023A2 (en) * 2008-07-01 2010-01-07 Zacharon Pharmaceuticals, Inc. Heparan sulfate inhibitors
EP2483406A2 (en) 2009-09-30 2012-08-08 President and Fellows of Harvard College Methods for modulation of autophagy through the modulation of autophagy-inhibiting gene products
JP5784296B2 (ja) * 2010-10-01 2015-09-24 学校法人 創価大学 神経細胞の製造方法及び神経細胞分化促進剤

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003503313A (ja) * 1999-06-03 2003-01-28 ジェシー エル エス オウ 細胞増殖及び細胞死を変調する方法及び組成物
US7129072B1 (en) * 1999-08-30 2006-10-31 New York University Crystal of fibroblast growth factor receptor 1 in complex with fibroblast growth factor
US20030147875A1 (en) * 2000-12-27 2003-08-07 Steven Rosen Sulfatases and methods of use thereof
AU2002355844A1 (en) * 2001-08-01 2003-02-17 New York University Identification of receptor and heparin binding sites in fgf4 by structure-based mutagenesis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of EP1742961A4 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009008496A1 (ja) * 2007-07-12 2009-01-15 Daiichi Sankyo Company, Limited 抗HSulf1抗体
WO2014138364A2 (en) 2013-03-06 2014-09-12 Genentech, Inc. Methods of treating and preventing cancer drug resistance
WO2015191986A1 (en) 2014-06-13 2015-12-17 Genentech, Inc. Methods of treating and preventing cancer drug resistance

Also Published As

Publication number Publication date
JP2007522243A (ja) 2007-08-09
WO2005079390A3 (en) 2006-12-14
CA2555417A1 (en) 2005-09-01
EP1742961A2 (en) 2007-01-17
US20050227921A1 (en) 2005-10-13
US7968527B2 (en) 2011-06-28
EP1742961A4 (en) 2009-07-15

Similar Documents

Publication Publication Date Title
Brodie et al. Protein kinase C-ε plays a role in neurite outgrowth in response to epidermal growth factor and nerve growth factor in PC12 cells
Allen et al. Role of heparan sulfate as a tissue-specific regulator of FGF-4 and FGF receptor recognition
Barnea et al. Receptor tyrosine phosphatase beta is expressed in the form of proteoglycan and binds to the extracellular matrix protein tenascin.
Walz et al. Essential role of heparan sulfates in axon navigation and targeting in the developing visual system
Poulain et al. Heparan sulfate proteoglycans: a sugar code for vertebrate development?
Sakuma et al. The functional role of calcineurin in hypertrophy, regeneration, and disorders of skeletal muscle
Grant et al. Cyclin‐dependent protein kinase 5 (Cdk5) and the regulation of neurofilament metabolism
Santos-Silva et al. FGF/heparin differentially regulates Schwann cell and olfactory ensheathing cell interactions with astrocytes: a role in astrocytosis
Yu et al. Flexible roles for proteoglycan sulfation and receptor signaling
Ohto et al. Identification of a novel nonlysosomal sulphatase expressed in the floor plate, choroid plexus and cartilage
Tran et al. Heparan sulfate 6-O-endosulfatases (Sulfs) coordinate the Wnt signaling pathways to regulate myoblast fusion during skeletal muscle regeneration
Tanga et al. The PTN‐PTPRZ signal activates the AFAP1L2‐dependent PI3K‐AKT pathway for oligodendrocyte differentiation: targeted inactivation of PTPRZ activity in mice
Bai et al. The post-translational modifications of Smurf2 in TGF-β signaling
Pathre et al. PTP1B regulates neurite extension mediated by cell‐cell and cell‐matrix adhesion molecules
Mason et al. SOST and DKK: antagonists of LRP family signaling as targets for treating bone disease
Finburgh et al. Role of FGF10/FGFR2b signaling in homeostasis and regeneration of adult lacrimal gland and corneal epithelium proliferation
Armendáriz et al. The diverse roles and multiple forms of focal adhesion kinase in brain
Hu et al. NDST1-dependent heparan sulfate regulates BMP signaling and internalization in lung development
Layer et al. Chicken retinospheroids as developmental and pharmacological in vitro models: acetylcholinesterase is regulated by its own and by butyrylcholinesterase activity
Shannon et al. Chondroitin sulfate proteoglycans are required for lung growth and morphogenesis in vitro
US7968527B2 (en) Inhibition of FGF signaling
Lin et al. SH2B1β enhances fibroblast growth factor 1 (FGF1)-induced neurite outgrowth through MEK-ERK1/2-STAT3-Egr1 pathway
Kaucká et al. Post‐translational modifications regulate signalling by Ror1
Gao et al. Fluoride regulates the expression of extracellular matrix HSPG and related signaling pathways FGFR3 and Ihh/PTHrP feedback loop during endochondral ossification
Jin et al. TGF‐β3 inhibits chondrogenesis of cultured chick leg bud mesenchymal cells via downregulation of connexin 43 and integrin β4

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2555417

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006553327

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWE Wipo information: entry into national phase

Ref document number: 2005713533

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005713533

Country of ref document: EP